US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
pharma · Osteoarthritis of Knee
KeyZell
Amzell
KeyZell drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
ES HQ
11 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- ES
- Employees
- 11
- Programs
- 1
- Drugs
- 1
- Patents
- 0
KeyZell pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
KeyZell drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.